Latitude Advisors LLC Lowers Position in Pfizer Inc. (NYSE:PFE)

Latitude Advisors LLC decreased its stake in shares of Pfizer Inc. (NYSE:PFE) by 14.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 17,484 shares of the biopharmaceutical company’s stock after selling 2,985 shares during the period. Latitude Advisors LLC’s holdings in Pfizer were worth $503,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Worth Asset Management LLC bought a new position in shares of Pfizer during the first quarter valued at about $29,000. Briaud Financial Planning Inc purchased a new position in shares of Pfizer in the 3rd quarter worth approximately $30,000. GoalVest Advisory LLC grew its holdings in shares of Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 811 shares in the last quarter. Mizuho Securities Co. Ltd. purchased a new stake in shares of Pfizer during the third quarter valued at approximately $34,000. Finally, VisionPoint Advisory Group LLC lifted its holdings in Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,047 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Down 0.8 %

Shares of Pfizer stock traded down $0.22 on Wednesday, reaching $25.69. The company had a trading volume of 28,885,313 shares, compared to its average volume of 33,467,946. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The firm’s 50-day moving average price is $27.23 and its two-hundred day moving average price is $28.79. Pfizer Inc. has a 1 year low of $25.61 and a 1 year high of $41.33. The firm has a market cap of $145.47 billion, a price-to-earnings ratio of 71.36, a P/E/G ratio of 1.18 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same period in the prior year, the business posted $1.14 earnings per share. The firm’s revenue for the quarter was down 41.3% compared to the same quarter last year. As a group, research analysts predict that Pfizer Inc. will post 2.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PFE has been the subject of a number of recent analyst reports. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research note on Thursday, January 4th. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Guggenheim assumed coverage on shares of Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective for the company. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Monday. Twelve analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $36.88.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.